The ICARA study is evaluating the safety and effectiveness of an investigational drug (bapineuzumab) aimed at slowing down the disease progression.
If you are between 50 and 88 years of age and have a diagnosis of probable Alzheimer's disease, you may be eligible to participate in the study.
Type in your ZIP code to locate a clinical site near you.